We are live on !
Find out more
P
Pfizer Portfolio holdings
AUM
$170M
Turnover
5.56%
1-Year Est. Return
191.09%
This Fund
S&P 500
This Quarter Est. Return
+6.77%
1 Year Est. Return
+191.09%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$170M
AUM Growth
-$68.4M
(-29%)
Cap. Flow
-$52.5M
Cap. Flow % of AUM
Cap. Flow %
-30.79%
Top 10 Holdings %
Top 10 Hldgs %
95.78%
Holding
18
New
–
Increased
–
Reduced
3
Closed
1
Avg Time Held
1.4
years
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
1.3
years
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oric Pharmaceuticals
ORIC
|
+$40M |
| 2 |
Zura Bio
ZURA
|
+$11M |
| 3 |
NextCure
NXTC
|
+$806K |
| 4 |
Q32 Bio
QTTB
|
+$737K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Allogene Therapeutics
ALLO
$449M
| $46.9M | 27.55% |
22,032,040
| – | – |
2024 Q4
6 quarters
|
|
2
Celcuity
CELC
$2.79B
| $29.6M | 17.35% |
295,652
| – | – |
2024 Q4
6 quarters
|
|
3
Arvinas
ARVN
$475M
| $27.7M | 16.24% |
3,457,815
| – | – |
2024 Q4
6 quarters
|
|
4
Pyxis Oncology
PYXS
$147M
| $19.5M | 11.43% |
7,032,770
| – | – |
2024 Q4
6 quarters
|
|
5
Wave Life Sciences
WVE
$625M
| $10.9M | 6.42% |
1,875,000
| – | – |
2024 Q4
6 quarters
|
|
6
Biohaven
BHVN
$1.71B
| $8M | 4.7% |
505,645
| – | – |
2024 Q4
6 quarters
|
|
7
Caribou Biosciences
CRBU
$49.7M
| $7.88M | 4.63% |
4,690,431
| – | – |
2024 Q4
6 quarters
|
|
8
Spero Therapeutics
SPRO
$65.2M
| $5.34M | 3.13% |
2,362,348
| – | – |
2024 Q4
6 quarters
|
|
9
Zentalis Pharmaceuticals
ZNTL
$218M
| $3.85M | 2.26% |
953,834
| – | – |
2024 Q4
6 quarters
|
|
|
10
Oric Pharmaceuticals
ORIC
$1.32B
| $3.55M | 2.09% |
372,904
-4,407,497
| -92% | -$40M |
2024 Q4
6 quarters
|
|
11
Cardiff Oncology
CRDF
$68.9M
| $3.01M | 1.77% |
2,411,575
| – | – |
2024 Q4
6 quarters
|
|
|
12
Zura Bio
ZURA
$365M
| $2.88M | 1.69% |
538,841
-2,300,072
| -81% | -$11M |
2024 Q4
6 quarters
|
|
13
AgomAb Therapeutics NV
AGMB
$405M
| $1.04M | 0.61% |
75,000
| – | – |
2026 Q1
1 quarter
|
|
14
Bolt Biotherapeutics
BOLT
$7.78M
| $134K | 0.08% |
31,305
| – | – |
2024 Q4
6 quarters
|
|
|
15
NextCure
NXTC
$26M
| $73K | 0.04% |
44,347
-109,007
| -71% | -$806K |
2024 Q4
6 quarters
|
|
16
Ginkgo Bioworks
DNA
$678M
| $30K | 0.02% |
2,928
| – | – |
2024 Q4
6 quarters
|
|
17
Senseonics Holdings Inc
SENS
$424M
| $12.4K | 0.01% |
2,171
| – | – |
2024 Q4
6 quarters
|
|
|
18
Q32 Bio
QTTB
$232M
| – | – |
-101,618
| Closed | -$737K | – |
|
Similar funds
BDS
WBCM
NL
WA
EWM
HP
GA
SVP
Pfizer's Q2 2026 Portfolio in Review
As of Q2 2026, Pfizer held 18 positions worth $170M, down 29% from $239M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
Pfizer withdrew a net $52.5M in Q2 2026, closing 1 position and reducing 3 holdings. Its most notable exit was Q32 Bio, an estimated $737K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Pfizer's biggest Q2 2026 reduction was Oric Pharmaceuticals, cutting an estimated $40M.
- Pfizer fully exited Q32 Bio in Q2 2026, selling an estimated $737K.
- Pfizer's ten largest holdings make up 96% of its $170M portfolio in Q2 2026.
- Pfizer opened 0 new positions and closed 1 in Q2 2026.
- Pfizer's portfolio value fell 29% quarter-over-quarter to $170M.
Based on Pfizer's 13F filing for Q2 2026, filed 13 Aug 2026.